Mechanisms of Trx2/ASK1-Mediated Mitochondrial Injury in Pemphigus Vulgaris

Bin Wei and Fenghe Li

1Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China
2Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China

Correspondence should be addressed to Bin Wei; wb_cmu@hotmail.com

Received 19 May 2020; Revised 16 January 2021; Accepted 8 February 2021; Published 23 February 2021

Objective. Apoptotic events mediated by mitochondrial injury play an important role on the onset of Pemphigus vulgaris (PV). The thioredoxin-2 (Trx2)/apoptosis signal-regulating kinase 1 (ASK1) signaling pathway is considered a key cascade involved on the regulation of mitochondrial injury. Hence, we have investigated the regulatory mechanism of the Trx2/ASK1 signaling in PV-induced mitochondrial injury.

Methods. Serum and tissue samples were collected from clinical PV patients to detect the oxidative stress factors, cell apoptosis, and expression of members from Trx2/ASK1 signaling. HaCaT cells were cultured with the serum of PV patients and transfected with Trx2 overexpression or silencing vector. Changes in the levels of reactive oxygen species (ROS), mitochondrial membrane potential (Δψm), and apoptosis were further evaluated. A PV mouse model was established and administered with Trx2-overexpressing plasmid. The efficacy of ectopic Trx2 expression towards acantholysis in PV mice was observed.

Results. A series of cellular and molecular effects, including (i) increased levels of oxidative stress products, (ii) destruction of epithelial cells in the skin tissues, (iii) induction of apoptosis in keratinocytes, (iv) reduction of Trx2 protein levels, and (v) enhanced phosphorylation of ASK1, were detected in PV patients. In vitro experiments confirmed that Trx2 can inhibit ASK1 phosphorylation, alleviate ROS release, decrease Δψm, and lower the apoptotic rate. Injection of Trx2-overexpressing vectors in vivo could also relieve acantholysis and blister formation in PV mice. Conclusion. The Trx2/ASK1 signaling pathway regulates the incidence of PV mediated by mitochondrial injury.

1. Introduction

Pemphigus vulgaris (PV) is one type of autoimmune blistering disease, related to chronic bullous dermatosis [1]. This condition is typically mediated by immunoglobulin G (IgG) autoantibodies which can dramatically affect the skin and mucosa of affected individuals [2]. In this case, many loose and fragile bullae may emerge at the site of the affected skin and mucosa, and the broken bullae form red erosions that can persist throughout the life of the patients. Studies have demonstrated that autoantibodies against desmoglein 1 (DSG-1) and DSG-3, which bind to DSG and then trigger the shrinkage and dissociation of epidermal keratinocytes (KCs), can be produced in PV patients, therefore leading to the formation of epidermal bullae [3]. Moreover, PV pathogenesis is associated with KC apoptosis induced by mitochondrial injury.

A number of studies have confirmed the presence of various types of mitochondria-related antibodies in the serum of PV patients [4, 5]. Such antibodies can directly enter into KCs and specifically recognize/bind a diverse number of receptors located in the mitochondrial surface [4]. Thereafter, these antibodies may lead to mitochondrial injury and initiate mitochondria-mediated host cell apoptosis, acantholysis, and desmosome attack [6]. Thus, neutralizing these antibodies may eliminate the IgG-induced KC dissociation (acantholysis) and vesicular lesions on the skin of PV patients.

The Trx system has crucial regulatory role on the redox status of living cells. The mitochondria-related Trx system
consists of three main components: Trx2, Trx reductase-2 (TrxR2), and peroxiredoxin-3 (Prx3) [7]. Apart from regulating the cellular redox status, Trx2 is also able to form a complex and inhibit the activation of ASK1 (apoptosis signal-regulating kinase 1) [8]. Once the levels of reactive oxygen species (ROS) are increased in the cell, the cysteine residues of Trx2 are oxidized, leading to the dissociation and activation of ASK1, which further triggers the cell apoptosis mediated by mitochondrial injury [9]. Therefore, here, we examined whether Trx2/ASK1 signaling could play a decisive role on the mitochondria-induced cell apoptosis during PV progression. The putative mechanism of action (MOA) of the Trx2/ASK1 pathway towards the KC apoptosis, induced by mitochondrial injury in PV patients, was presently investigated. Here, we provide novel insights for the development of a new target for the prevention and treatment of PV.

2. Materials and Methods

2.1. Tissue, Serum Collection, and Cell Culture. Serum and tissue samples were collected from 10 PV patients treated at the First Affiliated Hospital of Chongqing Medical University, between January and June 2018; 10 healthy people serum were also collected from the same hospital. The titer of antibody in patient’s serum and skin tissue against DSG-1 and DSG-3 was shown in Fig.S1A and Fig.S1B. As control, serum samples were also obtained from 10 normal subjects. This study was approved by the Ethics Committee of the Chongqing Medical University. All the patients signed an informed consent to participate in this study. HaCaT cells (human immortalized KCs) were purchased from China Center for Type Culture Collection. HaCaT cells were cultured in 5% CO₂ at 37°C in regular Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Invitrogen, Carlsbad, CA, USA) containing low concentration of Ca²⁺ (0.07 mM) and supplemented with 10% heat-inactivated fetal bovine serum.

2.2. Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick-End Labeling (TUNEL) Staining. A TUNEL staining kit (C1086, Beyotime, China) was utilized to detect the KC apoptosis in PV tissues. For this, skin tissues were embedded in paraffin blocks and then sliced to 4 μm thick sections, followed by deparaffinization with xylene. Sections were further incubated with DNase-free proteinase K (20 μg/mL), added dropwise at 37°C for 30 min, and then washed with phosphate-buffered saline (PBS) twice. Later, each section was treated with 50 μL of TUNEL assay solution and incubated in the dark at 37°C for 60 mins. After washing with PBS for 3 times, the sections were mounted using antifluorescence quenching medium, and then observed and photographed under a fluorescence microscope.

2.3. Enzyme-Linked Immunosorbent Assay (ELISA). The content of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) was determined by ELISA according to the manufacturers’ instructions (USCN, Wuhan, China). Specifically, 100 μL of each test sample or standard control was loaded into precoated ELISA plates and incubated at 37°C for 60 min. Subsequently, plate wells were washed with PBST and incubated with 50 μL of enzyme-labeled secondary antibody at 37°C for 30 min. After new round of washes, 50 μL of H₂O₂ and 50 μL of TMD were added per well and incubated in the dark at 37°C for 15 min. Thereafter, 50 μL of stop buffer solution was added into each well, and the absorbance at 450 nm was measured using a microplate reader. The enzymatic content of each sample was calculated according to respective standard curves. Moreover, the content of anti-desmoglein-1 and anti-desmoglein-3 in serum and skin tissue of PV patients were also detected by ELISA assay. The ELISA kits of anti-desmoglein-1 (SEA729Hu, Cloud-Clone Corp, Wuhan, China) and anti-desmoglein 3 (SEA444Hu, Cloud-Clone Corp, Wuhan, China) were used for examination. The experiment procedure was following with the instruction.

2.4. Western Blotting. Samples of PV skin tissues or cells were lysed in RIPA lysis buffer containing protease inhibitor. Total protein lysates were centrifuged to obtain the supernatant, from which the protein concentration was determined using a BCA kit. The protein content of each sample was subjected to SDS-PAGE, transferred onto membrane, and then blocked. Thereafter, membranes were incubated with respective primary antibodies against Trx2, ASK1, p-ASK1, SOD2, cleaved caspase-3, and GAPDH (diluted at 1 : 800) at 4°C overnight and with horseradish peroxidase-labeled secondary antibodies at room temperature for 2h. Specific protein bands were developed using an ECL kit and a gel imaging system. Absorbance values were analyzed using Image J.

2.5. Immunofluorescence (IF) Assay. PV skin tissues were first sliced using a freezing microtome, heated by microwaving (for antigen retrieval), and then incubated with normal goat serum at room temperature for 15 min. Anti-Trx2 antibody (1 : 500 solution) was added dropwise, and sliced tissues were then incubated at room temperature for 1 hr. Fluorescently labeled secondary antibody (1 : 500 solution) was further added dropwise for an additional one-hour incubation at room temperature. Subsequently, tissue sections were washed with PBS and then incubated with DAPI staining solution, in the dark, at room temperature for 10 min. After one last round of PBS washes, the sections were mounted in antifluorescence quenching medium and then observed/photographed under the fluorescence microscope.

2.6. Flow Cytometry. In vitro changes in ROS levels and mitochondrial membrane potential (Δψm) were examined by using a flow cytometer. In brief, HaCaT KCs were seeded into a 6-well plate at 5 × 10⁵ cells/well and cultured for 24 hr until adherence. Serum of normal controls and PV patients were then added separately. Cells were further treated with 5 μM JC-1 dye and 5 μM c-H2DCFDA-AM for 60 and 15 min, respectively, followed by flow cytometry analysis. The BD FACSDiVa software was used for data analysis.

2.7. Hematoxylin-Eosin (HE) Staining. Formalin-fixed skin samples from PV mice were dehydrated in gradient alcohol,
transparentized, and prepared into paraffin-embedded blocks. Afterwards, blocks were sliced into sections, subjected to HE staining, and mounted in neutral balsam. Stained sections were photographed under a light microscope (CX33, Olympus Corporation, Japan).

2.8. Statistical Analysis. Data were represented as mean ± standard deviation using the GraphPad Prism 8.0 software (GraphPad software, Inc., San Diego, CA, USA). Paired comparisons were conducted using a Student’s t-test. Intergroup comparisons were analyzed using one-way ANOVA followed by Tukey’s post hoc test. P < 0.05 was set as a cut-off for statistically significant differences.

3. Results

3.1. Mitochondrial Injury Induces KC Apoptosis in PV Patients. Antimitochondrial antibodies were reported to be generated in PV patients [10]. As a result, these antibodies can destroy the mitochondrial electron transport chain, thus causing the loss of transmembrane potential gradient in the inner mitochondrial membrane and, consequently, increasing the production of oxygen free radicals and weakening the resistance of KCs to oxidative stress [11, 12]. In regard to the oxidative stress products present in the PV patient sera, we currently verified that the content of GSH-Px was lowered, while the levels of SOD and CAT were increased (Figure 1(a)). The increase on oxidative stress products
apparently leads to the destruction of epithelial cells in the skin tissue and induces KC apoptosis (Figure 1(b)). Antibodies against SOD2 are common antimitochondrial immunoglobulins typically found in the PV patient sera. In this study, it was observed that both SOD2 and cleaved caspase-3 are highly expressed (Figure 1(c)), suggesting that mitochondrial injury may induce KC apoptosis in PV patients.

3.2. Trx2/ASK1 Pathway Is Abnormally Activated in PV Patients due to Mitochondrial Injury. The mitochondria-specific Trx system is an important player in apoptotic events induced by mitochondrial injury. Elevated ROS levels in PV patients can stimulate the oxidation of cysteine residues in the Trx2 protein, thereby promoting the dissociation of ASK1 from Trx2 complexes and then triggering the cell apoptosis mediated by mitochondrial injury. According to our results, the local expression of Trx2 was reduced in PV patients’ lesions (Figure 2(a)). According to the phosphorylation status of downstream proteins, Trx2 protein levels were reduced but, contrarily, the phosphorylation of ASK1 was enhanced (Figure 2(b)). These results indicate that the Trx2/ASK1 signaling cascade might be atypically induced in PV patients due to mitochondrial injury, thus promoting the occurrence and development of PV.

3.3. Trx2/ASK1 Signaling Mediates the Serum-Induced KC Apoptosis in PV Patients. HaCaT cells were cultured in media supplemented with sera from PV patients or normal (control) subjects. Western blot analysis indicated that Trx2 levels declined, while the phosphorylation level of ASK1 elevated in the cells culture with sera of PV patients (Figure 3(a)). Moreover, the levels of cleaved caspase-3 as well as the apoptotic rate in vitro were both increased (Figures 3(a) and 3(b)). In order to clarify the regulatory mechanism of Trx2/ASK1 signaling, a Trx2-overexpressing vector was constructed and transfected into cells. The apoptotic rate and the levels of cleaved caspase-3 in vitro were both reduced (Figures 3(a) and 3(b)). In contrast, the apoptotic rate of cells transfected with Trx2 silencing vector was elevated. Additionally, the apoptotic rate in vitro was further reduced upon treatment of Trx2-overexpressing cells with the ASK1-specific inhibitor GS-444217 (Figures 3(c) and 3(d)). These results suggest that the Trx2/ASK1 signaling cascade can modulate cell apoptosis in PV patients.

3.4. Trx2/ASK1 Signaling Controls the Serum-Induced Mitochondrial Injury in KCs of PV Patients. Mitochondrial antibodies are well detected in the sera of PV patients. At the same time, oxidative stress can induce cell apoptosis. In
Figure 3: Continued.

(a) Relative expression level of protein (Protein/GAPDH) for Trx2, ASK1, and Cleaved caspase-3. The expression is compared between Control and PV samples. Significant differences are indicated by *.

(b) Flow cytometry analysis showing the distribution of cells in different quadrants (Q1-UL, Q1-UR, Q1-LL, Q1-LR) for FITC-A and PI-A channels. The percentages of cells in each quadrant are indicated for Control, PV, PV+Trx2, and PV+siTrx2 samples. Significant differences are indicated by *.

(c) Relative expression level of p-ASK1 (p-ASK1/ASK1) for ASK1 and Cleaved caspase-3. The expression is compared between PV, PV+Trx2, and PV+siTrx2 samples. Significant differences are indicated by *.
this work, the detection of $\Delta \psi_m$ and ROS via flow cytometry demonstrated that the $\Delta \psi_m$ of HaCaT cells, cultured with PV patient sera, was enhanced (Figure 4(a)) and the ROS release was facilitated (Figure 4(b)). Upon Trx2 overexpression, both $\Delta \psi_m$ and ROS generation were decreased. These indicators decreased even more upon treatment with GS-444217, suggesting that the Trx2/ASK1 pathway might mediate the serum-induced mitochondrial injury in KCs of PV patients.

3.5. Trx2 Overexpression Prevents Acantholysis and Reduces KC Apoptosis in PV Mice. 20 BALB/c neonatal mice were injected with PV patient serum (100 $\mu$L/g) subcutaneously (s.c.); then, 10 BALB/c neonatal mice among them were treated with Trx2-overexpressing plasmid (0.1 $\mu$g/g) intraperitoneally (i.p.). 10 BALB/c neonatal mice were treated with the same amount of healthy person serum (100 $\mu$L/g) as control group. After 48 hours of s.c. injection, acantholysis, intraepidermal blister, and partial exfoliation occurred in the skin lesions and surrounding tissues in PV mice model. However, the epidermal structure was relatively intact, and the acantholysis was alleviated after i.p. injection of Trx2-overexpressing vector (Figure 5(a)). Furthermore, TUNEL assays indicated that Trx2 overexpression could lower the apoptotic rate of KCs in PV mice (Figure 5(b)). At the same time, Trx2 overexpression was also able to repress the phosphorylation level of ASK1 in PV mice (Figure 5(c)).

4. Discussion

As an organ-specific autoimmune disease, PV mainly affects the skin and mucosa and jeopardizes patients’ lives [13]. Based on the “desmoglein compensation hypothesis,” DSG antibodies currently play vital roles in the onset of PV [14]. Corticosteroid and immunosuppressants are traditional drugs used for PV therapy since they can ameliorate the disease conditions of patients [15]. Still, the side effects of hormonal therapies can increase the mortality rate of the patients. Therefore, seeking for an effective nonhormonal therapy for PV is of seminal significance for the prevention and treatment of this condition. In this study, we confirmed that the oxidative stress products are increased in PV. Due to this effect, epithelial cells from skin tissues are destroyed, and KC apoptosis is induced in PV patients. Besides, the mechanism of injury is apparently correlated with the aberrant activation of the Trx2/ASK1 signaling pathway, which is largely correlated with the mitochondrial injury in PV patients. Moreover, according to a number of in vivo experiments, we validated that Trx2 overexpression can alleviate the serum-induced mitochondrial injury and KC apoptosis in PV patients by inhibiting ASK1 phosphorylation.

Mitochondrial injury is a key pathogenic step in PV [16]. In fact, various mitochondrial antibodies exist in the serum of PV patients. These antibodies can directly enter in KCs to specifically recognize and bind a number of receptors on the surface of the mitochondria. Thereafter, such antibodies induce events linked to mitochondrial injury and initiate the mitochondria-mediated apoptosis, acantholysis, and desmosome attack [4]. More importantly, neutralizing these antibodies can eliminate the IgG-induced KC dissociation (acantholysis) as well as the vesicular lesions on the skin of PV patients.

Trx2 is a key player involved in the regulation of mitochondrial function [17, 18]. Here, we report that the local expression of Trx2 declines within the lesions of PV patients, while the phosphorylation level of its downstream protein ASK1 elevates. These observations indicate that the Trx2/ASK1 cascade is abnormally activated in PV patients affected by mitochondrial injury. Therefore, Trx2/ASK1 signaling appears to be directly related to the incidence of PV.

The mitochondria-specific Trx system includes three main components (i.e., Trx, TrxR, and Prx), and it has crucial regulatory effects on the redox status of cells [19]. In brief, Prx can directly remove ROS, while TrxR can reverse the
Figure 4: Trx2/ASK1 signaling controls the serum-induced mitochondrial injury in KCs of PV patients. (a) Flow cytometry was used to detect the $\Delta\psi_m$ marker JC-1; (b) flow cytometry was used to detect ROS. *$P < 0.05$. 
Figure 5: Continued.
oxidation status of Trx and thus restore the dual effects of oxidation and reduction. Apart from regulating the cellular redox status, Trx2 is capable of forming complexes with ASK1 and, consequently, to inhibit its activation. ASK1 is a type of serine/threonine kinase that can be activated during oxidative stress [20]. Once ROS levels are increased in the cell, the cysteine residues of Trx2 are oxidized, so that ASK1 is dissociated from Trx2 and activated, thereby triggering apoptotic events mediated by mitochondrial injury [8]. Several studies have indicated that the Trx2/ASK1 signaling pathway plays a decisive role in mitochondria-induced cell apoptosis [21]. Using KCs cultured with PV patient sera, here, we revealed that the levels of Trx2 were diminished, while ASK1 phosphorylation was enhanced. Upon Trx2 overexpression in vitro, both △ψm and ROS release were decreased, the apoptotic rate was lowered, and the expression of downstream proteins was inhibited. In order to elaborate the protective effect of Trx2 against PV, a PV mouse model was first established. After administration of Trx2 plasmid in PV mice, we notice that acantholysis was relieved and apoptotic rates were decreased. Taken together, Trx2 appears to inhibit ASK1 phosphorylation to further improve the mitochondrial injury and then reduce the apoptosis rate in PV, thus preventing the progression of this pathological condition.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interests.

Acknowledgments

This work was supported by the Youth Program of National Natural Science Foundation of China (81703127) and the Science and Technology Program of Chongqing (cstc2017jcyjA0778).

Supplementary Materials

Fig. S1: the clinic information of PV patients. (A) The content of DSG-1 and DSG-3 in serum detected by ELISA. (B) The content of DSG-1 and DSG-3 in skin lesion tissue detected by ELISA; n = 10 and * P < 0.05. (c) The immunohistochemistry results of DSG-1 and DSG-3 in skin tissue of PV patients and healthy people. (Supplementary Materials)

References

[1] M. Cholera and N. Chainani-Wu, "Management of pemphigus vulgaris," Advances in Therapy, vol. 33, no. 6, pp. 910–958, 2016.
[2] M. Kasperkiewicz, C. T. Ellebrecht, H. Takahashi et al., "Pemphigus," Nature reviews Disease primers, vol. 3, pp. 1–18, 2017.
[3] A. R. Ahmed, M. Carrozzo, F. Caux et al., "Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology," Experimental Dermatology, vol. 25, no. 11, pp. 839–846, 2016.
[4] Y. Chen, A. Chernyavsky, R. J. Webber, S. A. Grando, and P. H. Wang, "Critical role of the neonatal Fc receptor (FcRn) in the pathogenic action of antimitochondrial autoantibodies synergizing with anti-desmoglein autoantibodies in pemphigus vulgaris," Journal of Biological Chemistry, vol. 290, no. 39, pp. 23826–23837, 2015.
[5] S. C. Yeoh, K. Byth-Wilson, D. F. Murrell, M. Schifter, M. W. Lin, and D. A. Fulcher, "Pemphigus vulgaris disease activity: the role of antibodies to desmogleins and their isotype," Journal of Oral Pathology & Medicine, vol. 48, no. 7, pp. 619–625, 2019.
[6] A. Chernyavsky, Y. Chen, P. H. Wang, and S. A. Grando, "Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptosis," International Immunopharmacology, vol. 29, no. 1, pp. 76–80, 2015.
[7] H. Li, C. Xu, Q. Li et al., "Thioredoxin 2 offers protection against mitochondrial oxidative stress in H9c2 cells and against myocardial hypertrophy induced by hyperglycemia,"
International Journal of Molecular Sciences, vol. 18, no. 9, p. 1958, 2017.

[8] C. Liu, B. Cao, Q. Zhang et al., “Inhibition of thioredoxin 2 by intracellular methylglyoxal accumulation leads to mitochondrial dysfunction and apoptosis in INS-1 cells,” Endocrine, vol. 68, no. 1, pp. 103–115, 2020.

[9] C. Chen, H. Chen, H. J. Zhou, W. Ji, and W. Min, Mitochondrial Dynamics in Cardiovascular Medicine, Springer, 2017.

[10] M. Kalantari-Dehaghi, Y. Chen, W. Deng et al., “Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies,” Journal of Biological Chemistry, vol. 288, no. 23, pp. 16916–16925, 2013.

[11] N. Cirillo, E. Cozzani, M. Carrozzo, and S. Grando, “Urban legends: pemphigus vulgaris,” Oral Diseases, vol. 18, no. 5, pp. 442–458, 2012.

[12] M. Kalantari-Dehaghi, G. J. Anhalt, M. J. Camilleri et al., “Pemphigus vulgaris autoantibody profiling by proteomic technique,” PLoS ONE, vol. 8, no. 3, article e57587, 2013.

[13] A. G. de Macedo, E. R. Bertges, L. C. Bertges et al., “Pemphigus vulgaris in the mouth and esophageal mucosa,” Case Reports in Gastroenterology, vol. 12, no. 2, pp. 260–265, 2018.

[14] J. Liang, Y. Halipu, F. Hu et al., “Naringenin protects keratinocytes from oxidative stress injury via inhibition of the NOD2-mediated NF-κB pathway in pemphigus vulgaris,” Biomedicine & Pharmacotherapy, vol. 92, pp. 796–801, 2017.

[15] C. Chen, K. Wang, H. Zhang, H. J. Zhou, Y. Chen, and W. Min, “A unique SUMO-interacting motif of Trx2 is critical for its mitochondrial presequence processing and anti-oxidant activity,” Frontiers in Physiology, vol. 10, p. 1089, 2019.

[16] L. C. Puga Molina, D. M. Salvatierra Fréchou, and S. V. Verstraeten, “Early response of glutathione-and thioredoxin-dependent antioxidant defense systems to tl (i)- and tl (iii)-mediated oxidative stress in adherent pheochromocytoma (pc12adh) cells,” Archives of Toxicology, vol. 92, no. 1, pp. 195–211, 2018.

[17] J. T. Liles, B. K. Corkey, G. T. Notte et al., “ASK1 contributes to fibrosis and dysfunction in models of kidney disease,” The Journal of Clinical Investigation, vol. 128, no. 10, pp. 4485–4500, 2018.

[18] H. Y. Sun, Y. J. Hu, X. Y. Zhao et al., “Age-related changes in mitochondrial antioxidant enzyme Trx2 and TXNIP–Trx2–ASK 1 signal pathways in the auditory cortex of a mimetic aging rat model: changes to Trx2 in the auditory cortex,” The FEBS Journal, vol. 282, no. 14, pp. 2758–2774, 2015.